← Back to Clinical Trials
Recruiting NCT07032766

NCT07032766 Assessment of Morbidity and Mortality Following Serratus Anterior Plane Block (SAPB) for Unilateral Rib Fractures

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07032766
Status Recruiting
Phase
Sponsor Albert Einstein College of Medicine
Condition Pain Management
Study Type OBSERVATIONAL
Enrollment 220 participants
Start Date 2025-08-10
Primary Completion 2026-08

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 220 participants in total. It began in 2025-08-10 with a primary completion date of 2026-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to learn about the long-term effects of the serratus anterior plane block (SAPB) in adult patients who suffered multiple unilateral anterolateral rib fractures within 24 hours of patient presentation to the emergency department. The main question it aims to answer is: Does the SAPB for multiple anterolateral rib fractures demonstrate reduction in patient morbidity and mortality, including incidence of pneumonia, length of hospital stay, discharge disposition, and death, as compared to standard analgesic regimens. The SAPB will be performed if a physician trained in the SAPB is available within 24 hours of injury. If a trained physician is not available and the patient meets inclusion criteria, they will receive parental analgesia with opioid therapy. They will be followed until date of hospital discharge, up until 60 days.

Eligibility Criteria

Inclusion Criteria: * Patients over 18 years of age being treated in the Emergency Department at Jacobi Medical Center * Presenting within 24 hours of injury * Patient with 2 or more unilateral, anterior or lateral rib fractures * Able to provide consent (patient or health care proxy) * Clinical team believes the patient will require inpatient admission at the time of enrollment Exclusion Criteria: * Patients in traumatic arrest or hemodynamic instability * Patient expected to be discharged from the hospital within 24 hours * Prisoner * Pregnancy * Children less than 18 years of age * The patient is known or is suspected to be allergic to anesthetic * Significant pain from another traumatic and distracting injury * Patients without the ability to consent (or no health care proxy to consent) * Patients with bilateral or posterior rib fractures

Contact & Investigator

Central Contact

Ariella Gartenberg, MD

✉ ariella.applebaum@gmail.com

📞 2017871762

Principal Investigator

Michelle Montenegro, MD

PRINCIPAL INVESTIGATOR

Albert Einstein College of Medicine, Jacobi medical center

Frequently Asked Questions

Who can join the NCT07032766 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Pain Management. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07032766 currently recruiting?

Yes, NCT07032766 is actively recruiting participants. Contact the research team at ariella.applebaum@gmail.com for enrollment information.

Where is the NCT07032766 trial being conducted?

This trial is being conducted at The Bronx, United States.

Who is sponsoring the NCT07032766 clinical trial?

NCT07032766 is sponsored by Albert Einstein College of Medicine. The principal investigator is Michelle Montenegro, MD at Albert Einstein College of Medicine, Jacobi medical center. The trial plans to enroll 220 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology